Issued by Moderna
2022 was a pivotal year for Moderna. The last few years have demonstrated the profound potential of mRNA medicines to impact human health, and Moderna has evolved its Mission to deliver the greatest possible impact to people through mRNA medicines. In the second annual ESG Report, Moderna reflects on its commitments to tackle some of the biggest threats to human health, such as the urgent need to increase access to quality healthcare and medicines, inequalities affecting vulnerable communities around the world, and the increasing negative effects of climate change, and reports on how it advanced these strategies in 2022.
In its 2022 ESG Report, Moderna provides an update on how it is advancing its ESG strategy against five guiding focus areas for ongoing and future efforts:
The report also includes updates to the progress Moderna has made to date:
To read more, please visit: https://www.modernatx.com/responsibility/our-commitment
Executive Director, Communications
In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.